Mode
Text Size
Log in / Sign up
Phase 2 Completed N=346 Randomized Quadruple-blind Treatment

HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder

Source: ClinicalTrials.gov NCT02252536 ↗
Enrolled (actual)
346
Serious AEs
4.1%
Results posted
Sep 2018
Primary outcomePrimary: Percentage of Subjects With no Heavy Drinking Days (PSNHDD) — 17.3; 24.1 percentage of subjects with NHDD

Summary

The purpose of this study is to determine whether gabapentin enacarbil is effective in the treatment of problems with alcohol.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Subjects With no Heavy Drinking Days (PSNHDD)
17.3; 24.1
SECONDARY
Percentage of Subjects Abstinent From Alcohol (Key Secondary Endpoint)
16; 17
SECONDARY
Percentage of Subjects With a World Health Organization (WHO) Drinking Risk Category Decrease of at Least 1-level
107; 115
SECONDARY
Percentage of Subjects With a World Health Organization (WHO) Drinking Risk Category Decrease of at Least 2-levels
69; 80
SECONDARY
Percentage of Days Abstinent Per Week
49; 49.3
SECONDARY
Percentage of Heavy Drinking Days Per Week
46.5; 43.1
SECONDARY
Weekly Mean Number of Drinks Per Week
21.4; 23.1
SECONDARY
Weekly Mean Drinks Per Drinking Day
3.9; 4.1
SECONDARY
Cigarettes Per Week Among Smokers
61.4; 71
SECONDARY
Alcohol Craving Score [Alcohol Craving Scale - Short Form (ACQ-SR-R)]
2.5; 2.5
SECONDARY
Alcohol Related Consequences (ImBIBe) Score
8.3; 9.6
SECONDARY
Pittsburgh Sleep Quality Index (PSQI) Score
4.4; 4.9
SECONDARY
Beck Anxiety Inventory (BAI) Score
3.3; 4.6
SECONDARY
Beck Depression Inventory - II
5.2; 6.5

Eligibility Criteria

Inclusion Criteria

Subjects must meet each one of the following inclusion criteria in order to be eligible for participation in the study:

  • Be at least 21 years of age.
  • Have a current (past 12 months) DSM-5 diagnosis of AUD.
  • Have a BAC by breathalyzer equal to 0.000 when s/he signed the informed consent document (either just prior to or immediately after signing consent).
  • Be seeking treatment for problems with alcohol.

Additional will be evaluated in clinic.

Exclusion Criteria

Evaluations will be conducted in clinic.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02252536). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search